Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

Abstract: Road vehicle comprising a passenger compartment configured to accommodate a driver and at least one passenger alongside the driver; a vehicle dashboard; a steering wheel; a content display device comprises: a support element hinged in the area of a central portion of the vehicle dashboard, at the front between a driver's seat and a passenger's seat; at least one screen mechanically connected to the support element and configured to be visible to a passenger and/or to a driver while driving; a time measurement system, in particular a chronograph; the vehicle comprises mechanical controls arranged, namely mounted, in the area of the steering to give instructions to the time measurement system.

Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder. ADHD, Phelan-Mc-Dermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease. Brugada Syndrome. Short QT syndrome, or early repolarization syndrome.

Abstract: Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I), including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.

Abstract: Provided herein are compositions and methods for purifying and concentrating nucleic acids from large-volume samples. In particular, reagents are provided for non-specifically binding total nucleic acid to a solid surface, separating bound nucleic acid from a large-volume sample, separating nucleic acid from amplification inhibitors, and/or eluting nucleic acids into a small volume amenable to further analysis.

Abstract: A structured adsorbent assembly is described, which is usefully employed for pressure swing adsorption (PSA) processing of ambient air to generate high purity oxygen. The structured adsorbent assembly in various implementations may include cellulosic carbon molecular sieve fibers formed by spinning of precursor cellulose followed by pyrolysis of the spun fibers, as an argon-selective adsorbent, or AgX zeolite contained on and/or in polymeric fibers, as an argon-selective adsorbent, and such argon-selective adsorbents may be in combination with nitrogen-selective adsorbent such as LiX zeolite contained on and/or in polymeric fibers. The structured adsorbent assembly may be employed in PSA systems and processes to achieve highly efficient and economic generation of high purity oxygen for applications such as distributed gasification power generation.

Abstract: Synthesis gas containing nitrogen as the majority component is processed to increase the hydrogen to carbon dioxide ratio. Nitrogen, carbon dioxide, and other contaminants are subsequently removed by a purification unit to produce a purified hydrogen gas stream. A recycle stream within the purification unit helps achieve a hydrogen purity greater than 99.9 percent, and hydrogen recovery greater than 99 percent.

Abstract: A structured tissue belt assembly including a supporting layer, a non-woven web contacting layer, and one or more laser welds that attach the bottom surface of the web contacting layer to the top surface of the supporting layer. The structured tissue belt assembly allows for air flow in x, y and z directions. In exemplary embodiments, the structured tissue belt assembly has an embedment distance between the supporting layer and the web contacting layer of 0.05 mm to 0.60 mm and a peel force between the web contacting layer and the supporting layer of at least 650 gf/inch.

Abstract: A loom assembly includes a base including a storage area and a track, a first part disposed on one side of the base and a slider mounted to the track and spaced apart from the first part. The slider is movable along the track to set a distance between the first part. Each of the slider and the first part include features for holding multiple threads in place for the creation of beaded bracelets. The slider part further includes a top assembly including fingers that are disposed within slots to hold thread or string in place when forming a beaded or threaded item. The fingers are biased against an inner surface of a corresponding slot such that a thread placed within the slot is held between a finger and the wall of the slot.

Abstract: An aqueous solvent composition useful for CO2 capture is described, that includes one or more CO2-sorbing amines, e.g., an amino acid salt and a tertiary or a sterically hindered amine. The solvent composition may include one or more promoters that are effective to enhance solvent characteristics such as (i) CO2 sorption capacity, (ii) CO2 sorption rate, (iii) CO2 desorption capacity, (iv) CO2 desorption rate, and (v) regeneration temperature, in relation to a corresponding solvent lacking the promoters. In relation to existing CO2 capture solvent compositions, the disclosed aqueous solvent composition provides high solvent CO2 capacity, high rate of CO2 absorption and desorption, high thermal and oxidative stability, low solvent regeneration energy, low solvent emissions, and low solvent toxicity.

Abstract: A gas conditioning system removes contaminants including carbon dioxide from flue gas, such as flue gas of a marine vessel, and includes a rotating backed bed assembly. The rotating packed bed assembly fluidly connects to an exhaust port of an engine, and receive a flue gas from the exhaust port. The rotating packed bed assembly includes a first rotating packed bed having an absorption agent to absorb a portion of the carbon dioxide from the flue gas, and a second rotating packed bed to receive the absorption agent from the first rotating packed bed and desorb at least some of the portion of the carbon dioxide from the absorption agent.

Abstract: A gas conditioning system removes contaminants including nitrogen oxides and sulfur oxides from flue gas of a marine vessel, and includes an oxidizer unit and a direct contact cooler. The oxidizer unit receives an exhaust flue gas from a marine engine through a fluid inlet, such as at a temperature between 150 degrees Celsius and 550 degrees Celsius, and converts at least a portion of the nitrogen oxides in the flue gas into nitrogen gas, nitrogen dioxide, or both. The direct contact cooler is fluidly connected to the oxidizer unit, and includes a housing defining a cooling chamber. The direct contact cooler directs the flue gas into contact with seawater residing in the cooling chamber and cools the flue gas to a temperature less than or equal to 60 degrees Celsius. The seawater removes some or all nitrogen dioxide and sulfur dioxide from the flue gas in the cooling chamber.

Abstract: A gas conditioning system removes contaminants including nitrogen oxides and sulfur oxides from flue gas of a marine vessel, and includes an oxidizer unit and a direct contact cooler. The oxidizer unit receives an exhaust flue gas from a marine engine through a fluid inlet at a temperature between 150 degrees Celsius and 550 degrees Celsius, and converts at least a portion of the nitrogen oxides in the flue gas into nitrogen gas, nitrogen dioxide, or both. The direct contact cooler is fluidly connected to the oxidizer unit, and includes a housing defining a cooling chamber. The direct contact cooler directs the flue gas into contact with seawater residing in the cooling chamber and cools the flue gas to a temperature less than or equal to 60 degrees Celsius. The seawater removes some or all nitrogen dioxide and sulfur dioxide from the flue gas in the cooling chamber.

Abstract: A bioenergy generator to increase the life force of a biological system is provided. The bioenergy generator includes fine pieces of natural stone selected from the group of diamond, amethyst, tourmaline, jadestone with any color, and obsidian. The bioenergy generator includes fine pieces of natural sand selected from the group of white sand, black sand, pink sand, red sand, yellow sand, orange sand, and green sand. The bioenergy generator includes fine pieces of metal selected from the group of steel, iron, copper, zinc, aluminum, calcium, magnesium, silver, and gold. The bioenergy generator includes water and a supporting material operable to hold the natural sand, the natural stone, the metal, and the water together. Uses of the bioenergy generator are also provided, in particular, to enhance natural healing ability of a biological body and to treat a disease in a mammal.

Abstract: A spectrometer for detecting an electromagnetic (EM) wave spectrum having one or more wavelength components within a spectral band of interest, and a method of detecting an electromagnetic (EM) wave spectrum having one or more wavelength components within a spectral band of interest.

Abstract: Disclosed herein are medical devices, uses thereof, methods of manufacture, and kits comprising medical devices. Also disclosed herein are uses of medical devices. For example, medical devices are used to produced biophotons for biophoton therapy. Also disclosed herein is the administration of biophoton therapy for the treatment of stroke in a subject in need thereof.

Abstract: A dielectric barrier discharge plasma reactor and method in which plasma is used to activate difficult-to-activate molecules and the catalyst so that chemical conversion of the activated molecules can occur at reduced temperature and pressure conditions to carry out chemical reactions that ordinarily occur at high temperature and high pressure conditions or otherwise do not occur at all.

Abstract: A structured material assembly for removing CO2 from a gas, comprises a substrate, a sorbent for adsorbing CO2 from the gas, and a desorption material integrated into the structured material assembly, which is responsive to inputted energy to generate heat to desorb CO2 from the sorbent. The CO2-containing gas may comprise ambient air.

Abstract: A pharmaceutical composition or a health food composition for controlling blood sugar, raw materials of which include dioscoreae rhizome, medlar, and coconut oil. A preparation method for the composition includes: mixing dioscoreae rhizome and a decoction thereof with medlar for homogenization, pulverization and drying, and mixing the resultant product with coconut oil and water, followed by baking and drying. Further disclosed are a pharmaceutical preparation or a health food including the composition and an excipient, and a use of the composition in the preparation of a pharmaceutical preparation or a health food for reducing or eliminating diabetic conditions.

Abstract: A small intelligent robot system includes a main body including a right driving wheel and a left driving wheel at both sides thereof; a camera module that takes photos located above the main body; a speech recognition module that receives input indicative of a user request; and an internet connection processor that initiates a telephone call in response to the user request.